Projects & Publications

Oncology Outcomes

Oncology Outcomes (O2), a highly experienced resource group dedicated to real-world evidence data generation and integration. Through this collaboration, Roche and O2 will work together to increase RWD acceptability and accessibility across the Canadian ecosystem.


The GeneSolve Study examines the value of genomic sequencing for diagnosing childhood rare diseases. Through a cross-institutional collaboration with Oxford University, PACER is developing new ways to address the high levels of uncertainty introduced by multi-omics technologies. This multi-country approach to economic analyses will support the timely and appropriate adoption of genomics for better diagnosing and treating children with rare diseases across jurisdictions.


The Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) is the premier research organization for developing evidence-based information about the use of personalized / precision medicine.

Related Publications

  • Downie L, Amor DJ, Halliday J, Lewis S, Martyn M, Goranitis I. Exome Sequencing for Isolated Congenital Hearing Loss: A Cost-Effectiveness Analysis. Laryngoscope. 2020 Dec 31. doi: 10.1002/lary.29356. Epub ahead of print. PMID: 33382469.

  • Vellekoop H, Huygens S, Versteegh M, Szilberhorn L, Zelei T, Nagy B, Koleva-Kolarova R, Tsiachristas A, Wordsworth S, Rutten-van Mölken M; HEcoPerMed Consortium. Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine. Pharmacoeconomics. 2021 Apr 16. doi: 10.1007/s40273-021-01010-z. Epub ahead of print. PMID: 33860928.

  • Smith HS, McGuire AL, Wittenberg E, Lavelle TA. Family-level impact of genetic testing: integrating health economics and ethical, legal, and social implications. Per Med. 2021 May;18(3):209-212. doi: 10.2217/pme-2021-0016. Epub 2021 Mar 17. PMID: 33728981.

  • Pasmans CTB, Tops BBJ, Steeghs EMP, Coupé VMH, Grünberg K, de Jong EK, Schuuring EMD, Willems SM, Ligtenberg MJL, Retèl VP, van Snellenberg H, de Bruijn E, Cuppen E, Frederix GWJ. Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing. Expert Rev Pharmacoecon Outcomes Res. 2021 May 6:1-11. doi: 10.1080/14737167.2021.1917385. Epub ahead of print. PMID: 33852815.

  • van de Ven M, Simons MJHG, Koffijberg H, Joore MA, IJzerman MJ, Retèl VP, van Harten WH. Whole genome sequencing in oncology: using scenario drafting to explore future developments. BMC Cancer. 2021 May 1;21(1):488. doi: 10.1186/s12885-021-08214-8. PMID: 33933021; PMCID: PMC8088550.

  • Simons M, van de Ven M, Coupé V, Joore M, IJzerman M, Koffijberg E, Frederix G, Uyl-De Groot C, Cuppen E, van Harten W, Retèl V. Early technology assessment of using whole genome sequencing in personalised oncology. Expert Rev Pharmacoecon Outcomes Res. 2021 Apr 29. doi: 10.1080/14737167.2021.1917386. Epub ahead of print. PMID: 33910430.